Fostamatinib Disodium Patent Expiration

Fostamatinib Disodium is Used for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who had an insufficient response to previous treatment. It was first introduced by Rigel Pharmaceuticals Inc in its drug Tavalisse on Apr 17, 2018.


Fostamatinib Disodium Patents

Given below is the list of patents protecting Fostamatinib Disodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tavalisse US8771648 (Trimethoxyphenylamino) pyrimidinyl formulations Jul 27, 2032 Rigel Pharms
Tavalisse US8951504 (trimethoxyphenylamino) pyrimidinyl formulations Jul 27, 2032 Rigel Pharms
Tavalisse US7449458 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Sep 04, 2031 Rigel Pharms
Tavalisse US8263122 Wet granulation using a water sequestering agent Nov 24, 2030 Rigel Pharms
Tavalisse US8652492 Wet granulation using a water sequestering agent Nov 06, 2028 Rigel Pharms
Tavalisse US8163902 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms
Tavalisse US8445485 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms
Tavalisse US8912170 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms
Tavalisse US9283238 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 17, 2026 Rigel Pharms
Tavalisse US7989448 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jun 12, 2026 Rigel Pharms
Tavalisse US7538108 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Mar 28, 2026 Rigel Pharms
Tavalisse US8211889 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms
Tavalisse US9266912 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms
Tavalisse US9737554 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms
Tavalisse USRE48898 Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan 19, 2026 Rigel Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fostamatinib Disodium's patents.

Given below is the list recent legal activities going on the following patents of Fostamatinib Disodium.

Activity Date Patent Number
Patent litigations
Petition Decision - Accept Late Payment of Maintenance Fees - Granted 07 May, 2024 US9283238
Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted 07 May, 2024 US9283238
Petition to Accept Late Payment of Maintenance Fee Payment Filed 07 May, 2024 US9283238
Payment of Maintenance Fee, 8th Yr, Small Entity 07 May, 2024 US9283238
Surcharge, Petition to Accept Pymt After Exp, Unintentional. 07 May, 2024 US9283238
Expire Patent 22 Apr, 2024 US9283238
Payment of Maintenance Fee, 12th Yr, Small Entity 11 Mar, 2024 US8263122
Change in Power of Attorney (May Include Associate POA) 28 Feb, 2024 US8771648
Email Notification 28 Feb, 2024 US8652492
Email Notification 28 Feb, 2024 US8771648


Fostamatinib Disodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List